Insulin– tag –
-
First-in-Human Diabetes Cell Therapy Shows Promising Initial Clinical Data
The Medicine Maker UK Overview The world's first human diabetes cell therapy has reportedly shown promising initial data in clinical trials. This therapy holds the potential to reduce insulin dependency in Type 1 diabetes patients by rep... -
Medtronic Introduces Instinct Sensor, Expands MiniMed 780G System to Type 2 Diabetes with Dual FDA Clearances
Simply Wall St USA Overview Medtronic has expanded its diabetes sensor portfolio with the launch of the Instinct sensor, complementing its Simplera Sync™ and Guardian™ 4 sensors. The company also secured two key U.S. FDA regulatory miles... -
Diabeloop and ViCentra Launch Smartphone-Controlled DBLG2 System Integrated with Kaleido Patch Pump and Dexcom G7 CGM for Prescription in Germany
Press Release Hub Germany Overview Diabeloop and ViCentra have launched their DBLG2 Automated Insulin Delivery (AID) system for prescription in Germany, integrating ViCentra's Kaleido insulin patch pump with the Dexcom G7 Continuous Gluc... -
Dexcom G7 15-Day Continuous Glucose Monitor Authorized by Health Canada, Stelo CGM Cleared for Pediatric OTC Use by U.S. FDA
Business Wire, MarketScreener, CureCapture, Oura Member Care USA, Canada Overview Dexcom's G7 15-day continuous glucose monitoring (CGM) system has received Health Canada authorization for adults aged 18 and older, extending wear time to... -
Diabeloop and Vicentra Launch Smartphone-Controlled DBLG2 System Integrated with Dexcom G7 CGM in Europe
Press Release Hub (PA Media) UK Overview Diabeloop and Vicentra have jointly launched the smartphone-controlled DBLG2 system in the European market. This system integrates Vicentra's Kaleido insulin patch pump with the Dexcom G7 continuo... -
Novel Stem Cell Approach Aims for Functional Cure in Diabetes, Pioneering Immunosuppression-Free Islet Cell Transplantation
News-Medical International Overview A new stem cell approach is targeting a functional cure for diabetes, specifically focusing on the potential for islet cell transplantation without immunosuppression, as reported on July 11, 2026. This... -
Sana Biotechnology Announces Groundbreaking 14-Month Durability Data for Hypoimmune-Modified Islet Cell Transplantation (UP421) in Type 1 Diabetes Without Immunosuppression, Published in The New England Journal of Medicine
GlobeNewswire (Sana Biotechnology) USA Overview Sana Biotechnology announced groundbreaking long-term durability data for its hypoimmune-modified islet cell transplant UP421 in Type 1 Diabetes patients, demonstrating 14 months of sustain... -
Century Therapeutics Unveils Preclinical Data for iPSC-Derived Islet Replacement Therapy CNTY-813 for Type 1 Diabetes, Aiming for Immunosuppression-Free Treatment via Allo-Evasion™ 5.0 Technology and H2 2026 IND Filing
GlobeNewswire (Century Therapeutics) USA Overview Century Therapeutics announced that preclinical data for CNTY-813, its iPSC-derived islet replacement therapy for Type 1 Diabetes, will be presented at EASD 2026 and the Breakthrough T1D ... -
Cohort Study Confirms Primary Care-Initiated Continuous Glucose Monitoring Significantly Improves HbA1c and Reduces Hospitalizations in Insulin-Treated Diabetics
JAMA Network Open USA Overview A new cohort study published in JAMA Network Open demonstrates that initiating Continuous Glucose Monitoring (CGM) in insulin-treated adults with diabetes through primary care clinicians leads to clinically... -
FDA Clears Dexcom Stelo Glucose Biosensor as First Over-the-Counter CGM for Insulin-Naive Children Aged 2 and Up
U.S. Food and Drug Administration (FDA) USA Overview The U.S. FDA has granted the first over-the-counter (OTC) clearance for Dexcom's Stelo Glucose Biosensor System, expanding its use to insulin-naive children aged two and older. This la...
